Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of ...

Recursion is eliminating approximately 20% of its workforce, in a restructuring that reflects challenges seen across the biopharma industry.

Cardiovascular diseases cause one death every 33 seconds in America. Diagnosing these conditions, which account for approximately 20% of all deaths annually, can be difficult because the overlaying ...

OpenAI’s newest creation, the o3 model—billed as their “smartest and most capable to date”—rebelled against direct commands ...

Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical ...

Recursion Pharmaceuticals had a cash position of $509 million. Following Tuesday’s layoffs, the biotech expects its runway to ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $8.0, a ...

Recursion Pharmaceuticals said on Tuesday it would lay off about 20% of its workforce as the biotech company tries to cope with an industry-wide funding crunch and the current policy uncertainty.